Specifically blocking lysoPC-induced iPLA2β activation in ECs should prevent TRPC6 activation and preserve EC migration, thereby improving endothelial healing after interventions for cardiovascular diseases. This evidence concerns the gene TRPC6 and cardiovascular disorder.